



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: November 6, 2009

To: Primary Clinical Research Associates

From: Janis Wobschall
Research Protocol Specialist

Re: N0572: A Phase I/II trial of Sorafenib and CCI-779 in Recurrent Glioblastoma

The Pre-Registration (Step 1) Eligibility Checklist has been revised as follows:

Form Title	Brief Description of Edit
Pre-Registration (Step 1) Eligibility Checklist	<ul style="list-style-type: none">Deleted IRB approval/date verbiage

If you have any questions, please feel free to contact me at 507/284-4852.

JW/dg
Enclosure